These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 23372805)
1. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis. Lou-Qian Z; Rong Y; Ming L; Xin Y; Feng J; Lin X PLoS One; 2013; 8(1):e54970. PubMed ID: 23372805 [TBL] [Abstract][Full Text] [Related]
2. The Prognostic Value of p16 Hypermethylation in Cancer: A Meta-Analysis. Xing XB; Cai WB; Luo L; Liu LS; Shi HJ; Chen MH PLoS One; 2013; 8(6):e66587. PubMed ID: 23805242 [TBL] [Abstract][Full Text] [Related]
3. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications. González-Quevedo R; García-Aranda C; Morán A; De Juan C; Sánchez-Pernaute A; Torres A; Díaz-Rubio E; Balibrea JL; Benito M; Iniesta P Int J Oncol; 2004 Feb; 24(2):349-55. PubMed ID: 14719111 [TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers. Yoshino M; Suzuki M; Tian L; Moriya Y; Hoshino H; Okamoto T; Yoshida S; Shibuya K; Yoshino I Int J Oncol; 2009 Nov; 35(5):1201-9. PubMed ID: 19787276 [TBL] [Abstract][Full Text] [Related]
5. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations. Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260 [TBL] [Abstract][Full Text] [Related]
6. Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures. Tong J; Sun X; Cheng H; Zhao D; Ma J; Zhen Q; Cao Y; Zhu H; Bai J Lung Cancer; 2011 Nov; 74(2):155-63. PubMed ID: 21621871 [TBL] [Abstract][Full Text] [Related]
7. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Wang J; Wang B; Chen X; Bi J Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971 [TBL] [Abstract][Full Text] [Related]
8. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194 [TBL] [Abstract][Full Text] [Related]
9. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis. Ota N; Kawakami K; Okuda T; Takehara A; Hiranuma C; Oyama K; Ota Y; Oda M; Watanabe G Anticancer Res; 2006; 26(5B):3729-32. PubMed ID: 17094392 [TBL] [Abstract][Full Text] [Related]
11. Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis. Tan Z; Shen W Oncotarget; 2017 Apr; 8(16):27137-27144. PubMed ID: 28404927 [TBL] [Abstract][Full Text] [Related]
12. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590 [TBL] [Abstract][Full Text] [Related]
13. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. Qin K; Hou H; Liang Y; Zhang X BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713 [TBL] [Abstract][Full Text] [Related]
16. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Jarmalaite S; Kannio A; Anttila S; Lazutka JR; Husgafvel-Pursiainen K Int J Cancer; 2003 Oct; 106(6):913-8. PubMed ID: 12918069 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Zhan B; Lu D; Luo P; Wang B Clin Lab; 2016 Nov; 62(11):2203-2211. PubMed ID: 28164670 [TBL] [Abstract][Full Text] [Related]
18. [Abnormality of p16 gene and its clinicopathological significance in non-small cell lung cancer]. Fu J; Zhang J; Zhang HW Zhonghua Bing Li Xue Za Zhi; 2003 Apr; 32(2):133-6. PubMed ID: 12839675 [TBL] [Abstract][Full Text] [Related]
19. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Kim DH; Nelson HH; Wiencke JK; Zheng S; Christiani DC; Wain JC; Mark EJ; Kelsey KT Cancer Res; 2001 Apr; 61(8):3419-24. PubMed ID: 11309302 [TBL] [Abstract][Full Text] [Related]
20. Cigarette smoking and p16INK4α gene promoter hypermethylation in non-small cell lung carcinoma patients: a meta-analysis. Zhang B; Zhu W; Yang P; Liu T; Jiang M; He ZN; Zhang SX; Chen WQ; Chen W PLoS One; 2011; 6(12):e28882. PubMed ID: 22174919 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]